The Exploratory Clinical Trials on the Primary Safety and Effectiveness of High Myopic Posterior Scleral Fixation System

Inclusion Criteria: 1. Age 18\~65, male or female; 2. Refractive ranges from -6.00d to -25.00d; 3. The axial length of the operative eye was 26-32mm; 4. Macular cleavage 200-1000μm; 5. Corrected visual acuity of the operative eye \< 0.3; 6. Able to understand the purpose of the test, voluntarily participate and sign the informed consent form. Exclusion Criteria: 1. Known allergy to silica gel and patients with scar constitution; 2. Ocular inflammation; 3. Fundus hemorrhage; 4. Macular hole; 5. Macular cleavage of the contralateral eye greater than 200μm; 6. Corrected visual acuity of contralateral eye \< 0.4; 7. Opacity of the refractive medium; 8. Eye tumor; 9. History of hyperthyroidism; 10. Other ophthalmic concomitant diseases that cannot be controlled, such as diabetic retinopathy, hypertensive fundus lesions, optic nerve atrophy, etc.; 11. Severe impairment of liver and kidney function and/or severe systemic diseases (such as cardiovascular, respiratory, digestive, nervous, endocrine, genitourinary, etc., depending on the tolerance of surgery); 12. Women who are pregnant (determined by a blood pregnancy test at the first visit), who are preparing for pregnancy during the test, and who are breastfeeding; 13. a history of drug abuse or alcohol abuse; 14. participate in other drug or medical device clinical trials within 30 days prior to the screening of this clinical trial; 15. Any condition of the subject that the study physician considers to be an impediment to the clinical trial (e.g. subject's susceptibility to mental stress, uncontrollable mood, depression, etc.); 16. Poor compliance of the subject, unable to complete the test process as required.